Infantile hemangioma is a rapidly growing tumor that usually occurs during the e rst year of is life. It can be life-threatening if it affects vital structures, if it is combined with a thrombocytopenic coagulopathy (Kasabach-Merritt syndrome), or, if due to its large size, it diverts a large amount of blood e ow and causes hyperdynamic cardiac failure. Use of corticosteroids is the treatment of choice. Response rates vary between 30% and 60% (1). In the case of resistance to steroid treatment (40%‐70%), alternatives are needed (2). We present here three cases of children affected by life-endangering hemangiomas (one of them suffering from KasabachMerritt syndrome, another from a liver hemangioendothelioma and the third from a large posterior chest wall hemangioendothelioma) which did not respond to steroid treatment and were subsequently successfully treated with vincristine.
No takes yet. Share an insight, caveat, or question.
Perez et al. (2002) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: